FiercePharma24d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...
FierceBiotech28d
Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors
Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo ...
The Boston Globe28d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive ... the data “reflect a near worst-case scenario for this key pipeline program and raise considerable risk” around the drug’s potential in ...
Investopedia28d
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which ...
STAT29d
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
Vertex Pharmaceuticals said Thursday that its closely watched drug, suzetrigine, reduced pain compared to baseline but did not outperform a placebo in a Phase 2 study, raising doubts about the ...
The Motley Fool21d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
One of those, a program for treating acute pain, could be particularly lucrative. But that prospect is now in question. Vertex ran a phase 2 clinical trial investigating the efficacy of its non ...
Reuters29d
Vertex's painkiller results match placebo in study, shares tumble
Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a ...
The Motley Fool26d
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue ...
Bloomberg L.P.28d
Vertex Plummets With Pain Drug No Better Than Placebo in Study
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall. Vertex will continue testing ...
Business Wire27d
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Business Insider28d
Vertex Stock Falls After Release Of Phase 2 Results For Suzetrigine Study
(RTTNews) - Shares of Vertex Pharmaceuticals Inc. (VRTX) are falling on Thursday morning after its Phase 2 Study results using placebo showed improved or rather similar results, compared to the ...
Yahoo Finance3d
Vertex Pharmaceuticals Incorporated (VRTX)
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...